Estimated reading time: 0 minutes, 34 seconds

Merck Reaches $688M Class Action Settlement

In one of the top 25 securities class-action settlements of all time, pharmaceutical giant Merck agreed to pay $688 million to settle two lawsuits alleging the company didn’t act in the best interests of its shareholders, according to a recent article from USA Today.

At issue is that Merck delayed the release of a study showing that it’s cholesterol drugs Zetia and Vytorin didn’t work any better than a generic version of Merck's older cholesterol pill, Zocor. The company’s delay in releasing the results triggered criticism by analysts, investors and scientists.

The settlement must still be approved by a federal judge. Merck admitted no wrongdoing.

Read the full article from USA Today here.

Merck KGaA's logo
Enhanced by Zemanta
Read 3692 times
Rate this item
(0 votes)

Visit other PMG Sites:

PMG360 is committed to protecting the privacy of the personal data we collect from our subscribers/agents/customers/exhibitors and sponsors. On May 25th, the European's GDPR policy will be enforced. Nothing is changing about your current settings or how your information is processed, however, we have made a few changes. We have updated our Privacy Policy and Cookie Policy to make it easier for you to understand what information we collect, how and why we collect it.